Financial Contrast: Calidi Biotherapeutics (NYSE:CLDI) and Lexeo Therapeutics (NASDAQ:LXEO)

Calidi Biotherapeutics ( NYSE:CLDI – Get Your Free Report ) and Lexeo Therapeutics ( NASDAQ:LXEO – Get Your Free Report ) are both small-cap medical companies, but which is the better stock? We’ll compare the two companies based on risk strength, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Institutional and insider ownership

12.5% ​​of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 34.5% of Calidi Biotherapeutics shares are owned by insiders. Comparatively, 4.5% of Lexeo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, big money managers and endowments believe a company is poised for long-term growth.

return

This table compares Calidi Biotherapeutics and Lexeo Therapeutics’ net margins, return on equity and return on assets.

Earnings and Rating

This table compares the top-line revenue, earnings per share and valuation of Calidi Biotherapeutics and Lexeo Therapeutics.

Calidi Biotherapeutics has higher revenue, but lower revenue than Lexeo Therapeutics.

Analyst ratings

This is a summary of current ratings for Calidi Biotherapeutics and Lexeo Therapeutics, as reported by MarketBeat.

Calidi Biotherapeutics currently has a consensus price target of $16.67, indicating a potential upside of 1,516.24%. Lexeo Therapeutics has a consensus target price of $22.14, indicating a potential upside of 178.18%. Given Calidi Biotherapeutics’ higher probable upside, research analysts plainly believe Calidi Biotherapeutics is more favorable than Lexeo Therapeutics.

Summary

Lexeo Therapeutics beats Calidi Biotherapeutics on 6 of the 11 factors compared between the two stocks.

About Calidi Biotherapeutics

(Get a free report)

Calidi Biotherapeutics, Inc., a clinical-stage immuno-oncology company, is engaged in the development of allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product line includes CLD-101, which is in phase 1b clinical trial for the treatment of high-grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high-grade glioma; CLD-201, which is in preclinical study for the treatment of advanced solid tumors such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical study for the treatment of lung cancer and metastatic solid tumors. The company offers the NeuroNova platform and the SuperNova platform. The company is headquartered in San Diego, California.

About Lexeo Therapeutics

(Get a free report)

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company focusing on inherited and acquired diseases. The Company is developing LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreichs ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakofilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP-associated cardiomyopathy; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM, caused by the TNNI3 gene. It is also developing LX1001, an AAVrh10-based gene therapy candidate for the treatment of homozygous APOE4; LX1020, a gene therapy candidate for the treatment of homozygous APOE4; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was founded in 2017 and is headquartered in New York, New York.

Get news and reviews for Calidi Biotherapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Calidi Biotherapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.